Patheon's Swindon, UK facility has extended its aseptic vial-filling capabilities to include the commercial supply of small-scale specialty products. The facility recently received FDA approval at Swindon, allowing the company to provide clients with a seamless service, where development batches and commercial product can be supplied from the same filling line. This new capability is now operating at the Swindon site for vial sizes ranging from 2mL to 30mL, and allows for the use of disposable components.
Wes Wheeler, president and chief executive officer of Patheon, stated, "We can now produce commercial product from the same production line that is used for Phase II and Phase III clinical batches. This allows clients to commercialize their drugs much faster than would normally be expected."